Baxter International is shelling out $900 million on Sigma-Tau’s Oncaspar (pegaspargase) product portfolio, in a move designed to strengthen its commercial foothold in the global oncology market. Oncaspar is a first-line biologic used as part of a multi-agent chemotherapy regimen to treat the blood cancer acute lymphoblastic leukaemia (ALL), currently pulling in sales of around $100 million a year.
{iframe}http://www.pharmatimes.com/Article/15-05-12/Baxter_buys_Sigma-Tau_cancer_drugs_in_900m_deal.aspx{/iframe}